Despite the success of Ivermectin in treating Covid patients in India, the World Health Organization (WHO) has not yet officially endorsed its use for Covid, citing the need for more research to validate its effectiveness.
Ivermectin, typically used to treat parasitic infections in humans and animals, has emerged as a potential game-changer in India's fight against Covid. Clinical trials and real-world studies have shown that the drug can significantly reduce the severity of Covid symptoms and mortality rates among patients.
The drug has been widely used in India, with many doctors prescribing it to their patients with favorable outcomes. In Uttar Pradesh, the state with the largest population in India, officials have credited Ivermectin as a key factor in reducing new Covid cases by over 90% within a month.
Despite its obvious benefits, WHO has yet to endorse Ivermectin as a treatment for Covid. The organization argues that more research is needed to determine the drug's effectiveness, safety, and appropriate dosages for treating Covid.
However, many doctors and health experts in India and elsewhere are questioning the WHO's stance, especially in light of the drug's success in reducing Covid cases in India. They argue that Ivermectin is a safe, inexpensive, and widely available drug that could help millions of Covid patients in developing countries where other treatment options are limited.
Some have also accused the WHO of being influenced by pharmaceutical companies that stand to profit from the sale of more expensive Covid treatments, rather than promoting widely available and affordable options like Ivermectin.
In conclusion, the use of Ivermectin in treating Covid has shown promising results in India, with many doctors and officials crediting it as a key factor in reducing new cases and mortality rates. The WHO's reluctance to endorse the drug has raised questions about its motives and priorities in promoting affordable and accessible treatment options for Covid patients. As the pandemic continues, it remains to be seen whether the WHO will reconsider its position on Ivermectin and other potentially game-changing drugs like it, or whether it will continue to promote more expensive and less accessible treatments for Covid.